Plasmodium falciparum drug transporters and heme transport systems (PfTransporters)

Plasmodium falciparum transporters and heme transport systems represent a complex network of proteins essential for the survival and pathogenesis of the malaria parasite. These systems, primarily located on the plasma membrane and the digestive vacuole membrane, facilitate the uptake of essential nutrients and the efflux of metabolic waste products (Source: UniProt Q9N600, P13568). A critical function of these systems is the management of heme, a toxic byproduct generated during the digestion of host hemoglobin; the parasite must efficiently transport and sequester heme into non-toxic hemozoin crystals to prevent cellular damage (Source: PubMed 23873394). These transporters, most notably the Chloroquine Resistance Transporter (PfCRT) and Multidrug Resistance Protein 1 (PfMDR1), are the primary determinants of antimalarial drug resistance. Mutations in these proteins allow the parasite to expel therapeutic agents such as chloroquine and mefloquine from their sites of action, significantly complicating malaria treatment efforts globally. Consequently, these transport systems are major targets for both the development of new antimalarials and the design of resistance-reversing agents.

Other names

Malaria parasite efflux pumpsPlasmodium falciparum Chloroquine Resistance Transporter (PfCRT)Plasmodium falciparum Multidrug Resistance Protein 1 (PfMDR1)Plasmodium falciparum Multidrug Resistance-associated Protein (PfMRP)Plasmodium falciparum P-type ATPase 4 (PfATP4)Heme detoxification systemHeme transport protein

Antimalarial drugs often target these systems by inhibiting the biocrystallization of toxic heme into hemozoin or by being substrates for efflux, which determines their effective concentration at the target site. Newer agents like cipargamin inhibit specific transporters like PfATP4 to disrupt sodium homeostasis (Source: PubMed 20813921).